<DOC>
	<DOC>NCT01448057</DOC>
	<brief_summary>The study is a clinical evaluation of an over the counter (OTC) combination product containing paracetamol (500 mg), dimethindene maleate (1 mg), phenylephrine hydrochloride (10 mg) compared to paracetamol (500 mg) alone in the treatment of nasal congestion, rhinorrhea, sneezing and other symptoms due to upper respiratory tract infection (URTI).</brief_summary>
	<brief_title>Evaluation of Efficacy and Safety of Tablets of Paracetamol, Dimethindene Maleate and Phenylephrine Hydrochloride in Reducing Symptoms of Common Cold and Flu</brief_title>
	<detailed_description />
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Sneezing</mesh_term>
	<mesh_term>Phenylephrine</mesh_term>
	<mesh_term>Oxymetazoline</mesh_term>
	<mesh_term>Dimethindene</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>Inclusion criteria: â€¢ acute URTI, diagnosed by a health care professional at the study site, with the following symptoms having started within 72 hours before the screening/baseline Visit: nasal congestion, sneezing, and rhinorrhea. Exclusion criteria: Use of other investigational drugs within 30 days or 10 halflives before enrollment, whichever is longer. History of or known hypersensitivity to any of the study drugs, excipients or to drugs of similar chemical classes. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Paracetamol</keyword>
	<keyword>dimethindene maleate</keyword>
	<keyword>phenylephrine hydrochloride</keyword>
	<keyword>cold and flu symptoms</keyword>
</DOC>